Seagen

7465-CL-0301

NCT03474107

JCP043

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

3rd

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

Nectin4

Investigational

Product

Enfortumab Vedotin

Antibody‒Drug Conjugate (i.v.)

Treatment Arms

o  Arm A: Enfortumab Vedotin
Participants will receive enfortumab vedotin (EV) on days 1, 8 and 15 of each 28 day cycle.

o  Arm B: chemotherapy
Participants will receive the assigned drug (docetaxel, vinflunine or paclitaxel) on day 1 of every 21 day cycle.